Margriet V.D.Z. Park is an expert in innovative strategies and methods for human health risk assessment of nanotechnology and medical technology. She has over 10 years of experience as a senior scientist at the National Institute for Public Health and the Environment in the Netherlands, where she coordinates and manages international research projects and develops strategies and methods for risk assessment. She holds a PhD in Nanotoxicology from Maastricht University.
Anne Krug’s project measures human neurons, which are treated with different kinds of substances, to assess whether these have a negative impact on neurite growth.
The Karolinska Institute (KI) is the largest centre for medical education and research in Sweden and the home of the Nobel Prize in Physiology or Medicine.
KI consists of 22 departments and 600 research groups dedicated to improving human health through research and higher education.
The role of the Kohonen/Grafström team has been to guide the application, analysis, interpretation and storage of so called “omics” technology-derived data within the service-oriented subproject “ToxBank”.
Anne Krug’s project measures human neurons, which are treated with different kinds of substances, to assess whether these have a negative impact on neurite growth.
The Karolinska Institute (KI) is the largest centre for medical education and research in Sweden and the home of the Nobel Prize in Physiology or Medicine.
KI consists of 22 departments and 600 research groups dedicated to improving human health through research and higher education.
The role of the Kohonen/Grafström team has been to guide the application, analysis, interpretation and storage of so called “omics” technology-derived data within the service-oriented subproject “ToxBank”.
Dengue Virus Disease: Recent Updates on Vaccine DevelopmentRSIS International
This paper reviews the current experimental updates made in the development of a dengue vaccine particularly DNA and plant derived vaccine. Dengue is an endemic viral disease affecting human health particularly children. Till today there is no medication or treatment available for dengue. Vector control measures are not yet successful in controlling dengue transmission. Introduction of Wolbachia bacteria might be the new ray of hope for the effective dengue vector control measures. The development of an efficient dengue vaccine is difficult because vaccine must be tetravalent so that it includes all the serotypes. Therefore, a tetravalent formulation plays an important role in developing a dengue vaccine. Recently tetravalent French dengue vaccine, Dengvaxia (CYD-TDV) (Sanofi Pasteur’s, France) available (limited to a few countries) on the market since 2015. Sanofi branded, Dengavaxia (CYD-TDV) is the most promising one and has recently successfully completed the phase III clinical efficacy trials in Asia and Latin America. Dengavaxia (CYD-TDV) has been shown to be safe and has different levels of efficacy against the four serotypes. However, DNA vaccination has not yet successful mainly due to the insufficient immunogenicity. Botanical dengue vaccine production is also safe and have many advantages but there are still challenges that limit the rate of successful production of plant expressed vaccines. There are numerous dengue vaccine candidates in pipeline but none of them not yet promoting vaccination.
Bacteriological and Mycological Profile of Chronic Suppurative Otitis Media I...inventionjournals
International Journal of Pharmaceutical Science Invention (IJPSI) is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online.
The International Large Detector (ILD) is a concept for a detector at the International
Linear Collider, ILC. The ILC will collide electrons and positrons at energies of initially
500 GeV, upgradeable to 1 TeV. The ILC has an ambitious physics program, which will
extend and complement that of the Large Hadron Collider (LHC). The ILC physics case
has been well documented, most recently in the ILC Reference Design Report, RDR [1]. A
hallmark of physics at the ILC is precision. The clean initial state and the comparatively
benign environment of a lepton collider are ideally suited to high precision measurements.
To take full advantage of the physics potential of ILC places great demands on the detector
performance. The design of ILD, which is based on the GLD [2] and the LDC [3] detector
concepts, is driven by these requirements. Excellent calorimetry and tracking are combined to
obtain the best possible overall event reconstruction, including the capability to reconstruct
individual particles within jets for particle flow calorimetry. This requires excellent spatial
resolution for all detector systems. A highly granular calorimeter system is combined with a
central tracker which stresses redundancy and efficiency. In addition, efficient reconstruction
of secondary vertices and excellent momentum resolution for charged particles are essential
for an ILC detector. The interaction region of the ILC is designed to host two detectors,
which can be moved into the beam position with a “push-pull” scheme. The mechanical
design of ILD and the overall integration of subdetectors takes these operational conditions
into account. The main features of ILD are outlined in the present document.
CHEMICALLY DERIVED NANO-PIGMENT FOR ANTIBACTERIAL ACTIVITY, SURFACE COATING A...Jenson Samraj
This dissertation describes the properties of Nanopigment. The work which was furnished with lots of information about the antibacterial effects of the nanopigment.
Inside Opendoor: what two years of transactions say about their prospectsMike DelPrete
A data-driven analysis of Opendoor, the real estate disruptor, looking at its business model and traction since launch. Based on actual MLS data in its launch markets.
Dengue Virus Disease: Recent Updates on Vaccine DevelopmentRSIS International
This paper reviews the current experimental updates made in the development of a dengue vaccine particularly DNA and plant derived vaccine. Dengue is an endemic viral disease affecting human health particularly children. Till today there is no medication or treatment available for dengue. Vector control measures are not yet successful in controlling dengue transmission. Introduction of Wolbachia bacteria might be the new ray of hope for the effective dengue vector control measures. The development of an efficient dengue vaccine is difficult because vaccine must be tetravalent so that it includes all the serotypes. Therefore, a tetravalent formulation plays an important role in developing a dengue vaccine. Recently tetravalent French dengue vaccine, Dengvaxia (CYD-TDV) (Sanofi Pasteur’s, France) available (limited to a few countries) on the market since 2015. Sanofi branded, Dengavaxia (CYD-TDV) is the most promising one and has recently successfully completed the phase III clinical efficacy trials in Asia and Latin America. Dengavaxia (CYD-TDV) has been shown to be safe and has different levels of efficacy against the four serotypes. However, DNA vaccination has not yet successful mainly due to the insufficient immunogenicity. Botanical dengue vaccine production is also safe and have many advantages but there are still challenges that limit the rate of successful production of plant expressed vaccines. There are numerous dengue vaccine candidates in pipeline but none of them not yet promoting vaccination.
Bacteriological and Mycological Profile of Chronic Suppurative Otitis Media I...inventionjournals
International Journal of Pharmaceutical Science Invention (IJPSI) is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online.
The International Large Detector (ILD) is a concept for a detector at the International
Linear Collider, ILC. The ILC will collide electrons and positrons at energies of initially
500 GeV, upgradeable to 1 TeV. The ILC has an ambitious physics program, which will
extend and complement that of the Large Hadron Collider (LHC). The ILC physics case
has been well documented, most recently in the ILC Reference Design Report, RDR [1]. A
hallmark of physics at the ILC is precision. The clean initial state and the comparatively
benign environment of a lepton collider are ideally suited to high precision measurements.
To take full advantage of the physics potential of ILC places great demands on the detector
performance. The design of ILD, which is based on the GLD [2] and the LDC [3] detector
concepts, is driven by these requirements. Excellent calorimetry and tracking are combined to
obtain the best possible overall event reconstruction, including the capability to reconstruct
individual particles within jets for particle flow calorimetry. This requires excellent spatial
resolution for all detector systems. A highly granular calorimeter system is combined with a
central tracker which stresses redundancy and efficiency. In addition, efficient reconstruction
of secondary vertices and excellent momentum resolution for charged particles are essential
for an ILC detector. The interaction region of the ILC is designed to host two detectors,
which can be moved into the beam position with a “push-pull” scheme. The mechanical
design of ILD and the overall integration of subdetectors takes these operational conditions
into account. The main features of ILD are outlined in the present document.
CHEMICALLY DERIVED NANO-PIGMENT FOR ANTIBACTERIAL ACTIVITY, SURFACE COATING A...Jenson Samraj
This dissertation describes the properties of Nanopigment. The work which was furnished with lots of information about the antibacterial effects of the nanopigment.
Inside Opendoor: what two years of transactions say about their prospectsMike DelPrete
A data-driven analysis of Opendoor, the real estate disruptor, looking at its business model and traction since launch. Based on actual MLS data in its launch markets.
Human Genome Project is a worldwide scientific achievement. It was a thirteen-year project initiated in 1990 and completed in 2003. Human Genome Project helped a lot in the identification of diseased genes as DNA is very significant for understanding the diseased gene and their functions. It helped in the identification of disease loci for many diseases and presented their treatment through preventive measures. It identified the gene loci for many diseases like cancer, asthma, high blood pressure, diabetes type 2, obesity, Alzheimer's disease, Down's syndrome, Turner's syndrome, depression and many types of heart diseases including cardiovascular disease and coronary artery disease. This project does not directly treat the diseases but it helps in the identification of disease gene loci and then allows the treatment of disease through its preventive measures before the appearance of symptoms or at the initial stages of the disease through many techniques like gene therapy, pharmacogenomics, and targeted drug therapy. These are the helpful techniques in the diagnoses of the human disease gene locus.
Introduction to Robert F. Kennedy Jr. book available on Amazon. https://amzn.to/365aF8V
I created this PDF file of the intro to his book to give people a good idea what the book is about. I had no idea what I was getting into when I got the book. No people or person should be given as much power as Fauci, big pharma and big tech has.
Many thanks to Robert F Kennedy Jr for the time and effort he spent putting this together for the world to read.
Global Medical Cures™ | PCAST Report- Combating Antibiotic ResistanceGlobal Medical Cures™
Global Medical Cures™ | PCAST Report- Combating Antibiotic Resistance
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
A Study Regarding Knowledge of Anti Biotic Resistance among Engineering Stude...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
A Study Regarding Knowledge of Anti Biotic Resistance among Engineering Stude...
Margriet Park CV Jan 2017
1. Margriet V.D.Z. Park, PhD
Expert in innovative strategies and methods in the area of human health risk
assessment of nanotechnology and medical technology.
Vital Statistics
Name: Margriet van der Zee Park
Address: Utenhamstraat 2, 3451 BR
Vleuten, the
Netherlands
Telephone: +31 6 27576936
Email: margriet.park@gmail.com
Date of Birth: February 19, 1976
Place of Birth: Leeuwarden, the Netherlands
Nationality: Dutch
Key words
Critical analytical thinker with eye for detail, enthusiastic, fast learner, entrepreneurial,
innovative, determined.
Work experience
2011 – present
National Institute for Public Health and the Environment (RIVM)
Senior scientist nanotechnology and medical technology
• Acquisition of (inter)national research projects
• Coordination and management of (inter)national research projects
• Strategy and method development for risk assessment
• Supervision of PhD students
• Participation in expert committees
• Contribution to development of innovative software
• Monitoring scientific and regulatory developments
2007 – 2011
National Institute for Public Health and the Environment (RIVM)
Maastricht University, Department of Toxicogenomics
PhD thesis: Nanotoxicology – an in vitro approach
• Evaluation of use of in vitro assays for risk assessment of nanomaterials
• Investigation of possibilities to extrapolate safety data between nanomaterials
• Development of approach to determine adequate dose metrics for
nanomaterials
January 9, 2017 Margriet V.D.Z. Park CV
page 1
2. 2004-2007
National Institute for Public Health and the Environment (RIVM)
Scientist chemical risk assessment
• Development of chemical exposure assessment tool ConsExpo
• Exposure and risk assessment of chemicals in consumer products
• Chemical risk assessment of worker’s exposure
2002-2004
Lipid Nutrition Loders Croklaan B.V
Toxicologist
• Toxicological screening of potential food supplement ingredients
• Preparation of regulatory documents for registration of food supplement
ingredients
2001-2002
Michigan State University Aquatic Toxicology Laboratory
Research assistant
• Development of study proposal of the herbicide atrazine on the reproductive
success of amphibians.
• Participation in an Ecological Risk Assessments of the Kalamazoo River and
Tittabawassee River, Michigan Superfund Site
1995-1996
Development Aid from People to People (DAPP), Kukwanisa, Zimbabwe
Volunteer developmental aid
• Enrolling families in education programme on personal hygiene and lifesaving
skills
Academics
2007-2012 PhD; Nanotoxicology
Maastricht University
Department of Toxicogenomics
1996-2001 MSc; Biology
Wageningen University
1992-1994 International Baccalaureate
United World College of the Atlantic, Wales, UK
January 9, 2017 Margriet V.D.Z. Park CV
page 2
3. Training, registration and skills
2015 Entrepreneurship in practice
TIAS School for Business and Society
2015 Adverse Outcome Pathways
RIVM
2012 Mediatraining
Marcel Hamming MH Media BV
2010 Personal Efficiency Program
VWS
2010 Drug Development Cycle
TI Pharma
2009 Fysische Chemie 3 – Colloïden
Universiteit Utrecht
2008 S-Plus
RIVM
2008 Biostatistiek
Universiteit Utrecht
2006 Projectmatig werken
RIVM
2006 Immunotoxicologie
Universiteit Utrecht
2005 Principles of Toxicological Pathology
University of Surrey, UK
2004 Principles of Experimental Toxicology
and Risk Assessment
University of Surrey, UK
2004 Carcinogenicity and Mutagenicity
University of Surrey, UK
2002 Good Clinical Practice
DOCS, Zeist
2002 Biological Safety Training
Michigan State University, USA
2001 Radiation Safety Initial Training
Michigan State University, USA
2001 Chemical Hygiene and Laboratory
Safety Training
Michigan State University, USA
2000 Proefdierkunde
Universiteit Utrecht
• EUROTOX registered toxicologist since October 2006
• Excellent Dutch and English written and verbal communication
January 9, 2017 Margriet V.D.Z. Park CV
page 3
4. List of Publications
Giannakou C, Geertsma RE, de Jong WH, van Loveren H, Vandebriel R, Park MVDZ. 2016.
Immunotoxicity Testing of Nanomedicinal Products: Possible Pitfalls in Endotoxin
Determination. Current Bionanotechnology, in press.
Giannakou C, Park MVDZ, de Jong WH, van Loveren H, Vandebriel R, Geertsma RE. 2016.
A comparison of immunotoxic effects of nanomedicinal products with regulatory
immunotoxicity testing requirements. Int J Nanomed, 11, 293-2952.
Braakhuis HM, Giannakou C., Peijnenburg WJ, Vermeulen J., van Loveren H, Park MVDZ. 2016.
Simple in vitro models can predict pulmonary toxicity of silver nanoparticles. Nanotoxicology 10(6),
770-9.
Peijnenburg WJGM, Delmaar CJ, Oomen AG, Chen J, de Jong WH, Sips AJAM, Wang Z,
Park MVDZ. 2015. A practical approach to determine dose metrics for nanomaterials.
Environmental Toxicology and Chemistry 01/2015; 34(5). DOI:10.1002/etc.2878
Hougaard KS, Campagnolo L, Chavatte-Palmer P, Tarrade A, Rousseau-Ralliard D,
Valentino S, Park MVDZ, de Jong WH, Wolterink G, Piersma AH, Ross BL, Hutchison GR,
Hansen JS, Vogel U, Jackson P, Slama R, Pietroiusti A, Cassee FR. 2015. A perspective on
the developmental toxicity of inhaled nanoparticles Reproductive Toxicology 06/2015; 11.
DOI:10.1016/j.reprotox.2015.05.015
Braakhuis HM, Cassee FR, Fokkens PHB, de la Fonteyne LJJ, Oomen AG, Krystek WH, van
Loveren H, Park MVDZ. 2015. Identification of the appropriate dose metric for pulmonary
inflammation of silver nanoparticles in an inhalation toxicity study. Nanotoxicology
02/2015; DOI:10.3109/17435390.2015.1012184
Braakhuis HM, Kloet SK, Keziç S, Kuper F, Park MVDZ, Bellmann S, van der Zande M, le
Gac S, Krystek P, Peters RJB, Rietjens IMCM, Bouwmeester H. 2015. Progress and future
of in vitro models to study translocation of nanoparticles. Archives of Toxicology
05/2015; DOI:10.1007/s00204-015-1518-5
Noorlander CW, Kooi MW, Oomen AG, Park MVDZ, Vandebriel RJ, Geertsma RE. 2015.
Horizon scan of nanomedicinal products. Nanomedicine 02/2015; 10(10):1-10.
DOI:10.2217/nnm.15.21
Park MVDZ, Noorlander CW, Oomen AG, Vandebriel RJ, Geertsma RE. 2014.
Nanotechnologie – kansen en risico’s van nanogeneesmiddelen. MFM - Tijdschrift over
praktijkgerichte farmacotherapie 3-2014.
Braakhuis HM, Gosens I, Krystek P, Boere JAF, Cassee FR, Fokkens PHB, Post JA, van
Loveren H, Park MVDZ. Particle size dependent deposition and pulmonary inflammation
after short-term inhalation of silver nanoparticles. 2014. Particle and Fibre Toxicology
09/2014; 11(1):49. DOI:10.1186/s12989-014-0049-1
Braakhuis HM, Park MVDZ, Gosens I, de Jong WH, Cassee FR. 2014. Physicochemical
characteristics of nanomaterials that affect pulmonary inflammation. Particle and Fibre
Toxicology 04/2014; 11(1):18
January 9, 2017 Margriet V.D.Z. Park CV
page 4
5. Herberts CA, Park MVDZ, Pot JWGA, de Vries CGJCA. 2014. Results from a horizon scan
on risks associated with transplantation of human organs, tissues and cells: from donor
to patient. Cell and Tissue Banking 05/2014; DOI:10.1007/s10561-014-9450-0
Ahluwalia Arti, Ahtiainen Jukka, Aitken Robert, Alenius Harri, Christof Asbach, Toby
Athersuch, Ulrika Backman, Enrico Bergamaschi, Markus Berges, Jos Bessems, [...], Kees
van Gestel, Rob Vandebriel, Esa Vanhala, Socorro Vázquez-Campos, Minnamari Vippola,
Ulla Vogel, Frank von der Kammer, Peter Wick, Margrethe Winther-Nielsen, Volkan Özgüz
et al. 2013. Nanosafety in Europe 2015-2025: Towards Safe and Sustainable
Nanomaterials and Nanotechnology Innovations 2013. Finnish Institute of Occupational
Health, Helsinki., ISBN: 978-952-261-310-3; 978-952-261-311-0
Krystek P, Park MVDZ, Braakhuis H, Jong WH. 2013. Applications of Inductively Coupled
Plasma-Mass Spectrometry in Biodistribution Studies of (Engineered) Nanoparticles.
Encyclopedia of Analytical Chemistry: Wiley & Sons, Ltd.
De Jong WH, van der Ven LT, Sleijffers A, Park MVDZ, Jansen EH, van Loveren H. 2013
Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated
dose toxicity study in rats. Biomaterials 34(33):8333-43.
Park MVDZ, Lynch I, Ramírez-García S, Dawson KA, de la Fonteyne L, Gremmer E, Briedé
JJ, Slob W, Elsaesser A, Howard CV, Van Loveren H, De Jong W. 2011. In vitro evaluation
of cytotoxic and inflammation properties of silica nanoparticles of different sizes in
murine RAW 264.7 macrophages. J Nanopart Res 13(12):6775-6787.
Park MVDZ, Neigh AM, Vermeulen JP, de la Fonteyne LJ, Verharen HW, Briede JJ, van
Loveren H, de Jong WH. 2011. The effect of particle size on the cytotoxicity,
inflammation, developmental toxicity and genotoxicity of silver nanoparticles.
Biomaterials 32(36):9810-7.
Colognato R, Park MVDZ, Wick P, De Jong WH. 2012. Interactions with the Human Body.
In: Adverse Effects of Engineered Nanomaterials: Exposure, Toxicology and Impact on
Human Health. Fadeel B, Pietroiusti A, Shvedova AA, editors. Amsterdam: Elsevier.
Park MVDZ, Verharen HW, Zwart E, Hernandez L, van Benthem J, Elsaesser A, Barnes C,
McKerr G, Salvati A, Lynch I, Dawson KA, de Jong WH. 2011. Genotoxicity evaluation of
silica nanoparticles of different sizes using the micronucleus and the plasmid lacZ gene
mutation assay. Nanotoxicology 5:168-81.
Park MVDZ, Annema W, Salvati A, Lesniak A, Elsaesser A, Barnes C, McKerr G, Howard
CV, Lynch I, Dawson KA et al. 2009. In vitro developmental toxicity test detects
inhibition of stem cell differentiation by silica nanoparticles. Toxicol Appl Pharmacol
240:108-116.
Park MVDZ, Lankveld DPK, van Loveren H, de Jong W. 2009. The status of in vitro
toxicity studies in risk assessment of nanomaterials. Nanomedicine 4(6):669-685.
January 9, 2017 Margriet V.D.Z. Park CV
page 5
6. O' Shea, M., Van der Zee, M. and Mohede, ICM. Conjugated Linoleic Acids - Sources and
Clinical Studies (2005) IN: Healthful Lipids. American Oil Chemists' Society (AOCS) p249-
272.
January 9, 2017 Margriet V.D.Z. Park CV
page 6
7. O' Shea, M., Van der Zee, M. and Mohede, ICM. Conjugated Linoleic Acids - Sources and
Clinical Studies (2005) IN: Healthful Lipids. American Oil Chemists' Society (AOCS) p249-
272.
January 9, 2017 Margriet V.D.Z. Park CV
page 6